Messenger RNA (mRNA) technology will change modern medicine, especially in vaccine development, as seen in the frantic pace with which COVID-19 vaccines were developed. But it is not only restricted to infectious diseases; it can be applied similarly promisingly in dermatology. Skin diseases such as vitiligo, psoriasis, and atopic dermatitis can be addressed through mRNA-based therapy. It is a potent, more targeted, and non-permanent way of treating skin diseases, which seems to be safer. This article discusses exploring the possible applications of mRNA technology in dermatology, focusing on the treatment of vitiligo. 

Understanding mRNA Technology in Dermatology

mRNA technology replaces a biological way of treatment involving their synthetic mRNA into healthy or diseased cells, where the mRNA is designed for customized therapeutic proteins that can be willed to manage certain diseases by the skin. Skin cells can thus be instructed to produce necessary proteins responsible for pigmentation, immune regulation, or tissue repair. This could be multidisciplinary between skin cells. Unlike gene therapy (involves the nonremovable modification of genes), with mRNA, the effects are short-lived, which serves to prevent long-ranging implications of adverse effects. 

Vitiligo: Pathophysiology and Current Treatments

The term vitiligo denotes a skin disease with an autoimmune basis leading to the destruction of melanocytes and the appearance of depigmented patches on the skin surface. The disease is hypothesized to be potentially connected to certain genetic, environmental, and immunological factors, particularly the development of aberrant immune responses. Modern treatment options comprise topical corticosteroids, calcineurin inhibitors, phototherapy, and surgery, but each of these treatments is characterized by poor efficacy, potentially significant side effects, and different degrees of success (Ezzedine et al., 2015). 

Potential of mRNA-Based Therapies for Vitiligo

mRNA technology could potentially revolutionize the treatment of vitiligo by acting directly against the melanocyte destructive mechanism and immune dysregulation. Here are some possible approaches to explore: 

1. Restoring Melanocyte Function: It may be hard for skin cells to produce proteins essential for melanocyte survival and function, stimulated by mRNA therapy. For instance, upon injection, mRNA may encode for either tyrosinase, MITF, or endothelin-1, proteins involved in melanogenesis and pigment production, restoring pigment to the affected area (Picardo & Dell’Anna, 2018). 

2. Modulating Immune Responses: Certainly! It can be said that mRNA-based therapies have a potential ability to control autoimmune responses directed to melanocyte. A delivery vehicle for certain mRNAs coding anti-inflammatory cytokines such as interleukin-10 (IL-10) or transforming growth factor-beta (TGF-β) might benefit the immune-mediated destruction of melanocytes (Wang et al., 2021). 

3. Stimulating Repigmentation with Growth Factors: mRNA could act to promote the expression of growth factors, such as basic fibroblast growth factor (bFGF) or hepatocyte growth factor (HGF), known to stimulate melanocyte proliferation and migration (Buchanan et al., 2017). 

Advantages of mRNA-Based Dermatology Treatments 

mRNA-based therapies show many advantages compared to treatment of vitiligo as follows:  

  • Customization and Precision: mRNA can be selectively designed to target distinctive molecular pathways involved in vitiligo pathogenesis.  
  • Temporary Action: mRNA does not afford permanent modification of the DNA, thus alleviating potential risks invoked by gene therapy.   
  • Minimal Systemic Side Effects: Localized mRNA delivery provides targeted action to the skin with negligible systemic adverse effects.  
  • Potential for Combination: mRNA therapy can be augmented by its combination with current treatments like phototherapy or topical immunomodulators to enhance potency. 

Challenges and Future Directions

Nevertheless, there are some challenges mRNA-type dermatology treatments would still have to contend with:  

  • Delivery Systems: Even though there have been several trials with lipid nanoparticles (LNPs) and microneedle patches as possible options for delivery (Sahin et al., 2019), it is still a challenge for companies or researchers in developing reliable and safe methods to deliver mRNA to target skin cells.  
  • Stability and Longevity: mRNA is inherently instable and modifications need to be made to improve and prolong their effects.  
  • Immune Reactions: Even though mRNA treatments are said to be immunologically safe, it is recommended to monitor the other immune adverse responses.  
  • Clinical Translation: For mRNA treatments for vitiligo, there are multiple sets of pre-clinical and clinical trials before the safety and efficacy of the treatment could be proven to be true. 

mRNA technology is thus an exciting new territory in dermatology that can be opened for the treatment of such conditions as vitiligo. If the goal is to possibly restore pigmentation or modulate immune response, even stimulate melanocyte function, investigators aim toward therapies that would put forward mRNA to direct protein synthesis. Challenges remain, but advances in the design of delivery systems and molecular engineering will facilitate these developments toward their clinical applications in not too distant a future. Such mRNA-based developments in dermatology will radically reshape the field of skin diseases as the science towards clinical application matures, providing hope to millions suffering from vitiligo and other chronic skin conditions. 

References

  1. Buchanan, P. J., Dai, C., Mahoney, M. M., & Omori, K. (2017). Mechanisms of melanocyte response to fibroblast growth factors in skin pigmentation. Experimental Dermatology, 26(7), 583-589. https://doi.org/10.1111/exd.13358 
  2. Ezzedine, K., Eleftheriadou, V., Whitton, M., & van Geel, N. (2015). Vitiligo. The Lancet, 386(9988), 74-84. https://doi.org/10.1016/S0140-6736(14)60763-7 
  3. Picardo, M., & Dell’Anna, M. L. (2018). Vitiligo: Targeting the loss of pigmentation. Nature Reviews Disease Primers, 4(1), 1-18. https://doi.org/10.1038/s41572-018-0025-z 
  4. Sahin, U., Kariko, K., & Tureci, O. (2019). mRNA-based therapeutics—Developing a new class of drugs. Nature Reviews Drug Discovery, 18(10), 759-780. https://doi.org/10.1038/s41573-019-0050-5 
  5. Wang, X., Du, J., Wang, X., & Wang, C. (2021). The role of immune cells in vitiligo pathogenesis. Frontiers in Immunology, 12, 606298. https://doi.org/10.3389/fimmu.2021.606298 

RELATED ARTICLESMORE FROM AUTHOR